USANA Health Sciences (USNA) Projected to Post Quarterly Earnings on Tuesday

USANA Health Sciences (NYSE:USNA - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, July 22nd. Analysts expect USANA Health Sciences to post earnings of $0.54 per share and revenue of $225.20 million for the quarter. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings data on Tuesday, April 22nd. The company reported $0.73 earnings per share for the quarter, topping analysts' consensus estimates of $0.70 by $0.03. The firm had revenue of $249.54 million during the quarter, compared to analysts' expectations of $243.08 million. USANA Health Sciences had a return on equity of 8.94% and a net margin of 3.98%. During the same period in the prior year, the business posted $0.86 EPS. On average, analysts expect USANA Health Sciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

USANA Health Sciences Stock Down 0.0%

Shares of NYSE USNA traded down $0.00 during mid-day trading on Wednesday, reaching $31.32. 95,666 shares of the company were exchanged, compared to its average volume of 141,363. The stock has a market cap of $583.12 million, a price-to-earnings ratio of 17.21, a P/E/G ratio of 1.00 and a beta of 0.64. USANA Health Sciences has a 1 year low of $23.10 and a 1 year high of $48.85. The firm has a 50-day moving average of $30.59 and a 200 day moving average of $30.28.

Insiders Place Their Bets

In related news, CFO G Doug Iiekking sold 4,548 shares of the company's stock in a transaction on Friday, May 9th. The stock was sold at an average price of $29.61, for a total transaction of $134,666.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Walter Noot sold 6,291 shares of the stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $30.29, for a total value of $190,554.39. The disclosure for this sale can be found here. Insiders have sold a total of 12,013 shares of company stock valued at $360,149 over the last 90 days. 0.63% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On USANA Health Sciences

A hedge fund recently raised its stake in USANA Health Sciences stock. AQR Capital Management LLC raised its holdings in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 82.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,845 shares of the company's stock after buying an additional 9,894 shares during the quarter. AQR Capital Management LLC owned about 0.12% of USANA Health Sciences worth $589,000 at the end of the most recent reporting period. 54.25% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded USANA Health Sciences from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.